• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Genelux Corporation

    10/25/24 9:45:20 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GNLX alert in real time by email
    SC 13G 1 p24-2996sc13g.htm GENELUX CORP
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. )*
     

    Genelux Corporation

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    36870H103

    (CUSIP Number)
     

    September 30, 2024

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 6 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 36870H10313GPage 2 of 6 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Highbridge Capital Management, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    2,500,000 shares of Common Stock issuable upon the exercise of warrants

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    2,500,000 shares of Common Stock issuable upon the exercise of warrants

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,500,000 shares of Common Stock issuable upon the exercise of warrants

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.8%

    12

    TYPE OF REPORTING PERSON

    IA, OO

             

     

     

    CUSIP No. 36870H10313GPage 3 of 6 Pages

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Genelux Corporation (the “Company”).

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 2625 Townsgate Road, Suite 230, Westlake Village, CA 91361.

     

    Item 2(a). NAME OF PERSON FILING:

     

     

    This statement is filed by Highbridge Capital Management, LLC (“Highbridge” or the “Reporting Person”), a Delaware limited liability company and the investment adviser to certain funds and accounts (the “Highbridge Funds”), with respect to the shares of Common Stock (as defined in Item 2(d) below) underlying warrants directly held by the Highbridge Funds.

     

      The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the securities reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

     

      The address of the business office of the Reporting Person is 277 Park Avenue, 23rd Floor, New York, New York 10172.

     

    Item 2(c). CITIZENSHIP:

     

      Highbridge is a Delaware limited liability company.  

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.001 per share (the “Common Stock”).

     

    Item 2(e). CUSIP NUMBER:
       
      36870H103

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act,
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act,
      (c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act,
      (d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940,

     

     

    CUSIP No. 36870H10313GPage 4 of 6 Pages

     

      (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨ Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F),
      (g) ¨ Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),
      (h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:________________________________________

     

    Item 4. OWNERSHIP.
       
     

    The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page of the Reporting Person and is incorporated herein by reference.

     

    The percentages set forth herein are calculated based upon 34,535,471 shares of Common Stock reported to be outstanding as of August 12, 2024, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the Securities and Exchange Commission on August 14, 2024, and assumes the exercise of the warrants held by the Highbridge Funds.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      Not applicable.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      See Item 2.  The Highbridge Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock reported herein.  Highbridge Tactical Credit Master Fund, L.P., a Highbridge Fund, has the right to receive or the power to direct the receipt of dividends or the proceeds from the sale of more than 5% of the Common Stock.  

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

     

     

     

    CUSIP No. 36870H10313GPage 5 of 6 Pages

     

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable
       
    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.

     

      The Reporting Person hereby makes the following certification:
     

     

    By signing below the Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

       

     

    CUSIP No. 36870H10313GPage 6 of 6 Pages

    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATED: October 25, 2024

     

    HIGHBRIDGE CAPITAL MANAGEMENT, LLC
         
         
    By: /s/ Kirk Rule  
    Name: Kirk Rule  
    Title: Executive Director  
         

     

    Get the next $GNLX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GNLX

    DatePrice TargetRatingAnalyst
    10/29/2024$8.00Buy
    Guggenheim
    8/28/2024$10.00Buy
    ROTH MKM
    11/27/2023$35.00Buy
    H.C. Wainwright
    9/12/2023$40.00Buy
    Maxim Group
    2/15/2023$10.00Speculative Buy
    The Benchmark Company
    More analyst ratings

    $GNLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Genelux Corporation

      SC 13G - GENELUX Corp (0001231457) (Subject)

      10/25/24 9:45:20 AM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Genelux Corporation

      SC 13G/A - GENELUX Corp (0001231457) (Subject)

      10/22/24 4:12:19 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Genelux Corporation

      SC 13G - GENELUX Corp (0001231457) (Subject)

      2/2/24 4:06:25 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNLX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Genelux Corporation

      10-Q - GENELUX Corp (0001231457) (Filer)

      5/6/25 4:06:34 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Genelux Corporation

      10-K/A - GENELUX Corp (0001231457) (Filer)

      4/29/25 4:05:19 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Genelux Corporation

      S-8 - GENELUX Corp (0001231457) (Filer)

      3/28/25 4:29:17 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Genelux with a new price target

      Guggenheim initiated coverage of Genelux with a rating of Buy and set a new price target of $8.00

      10/29/24 6:26:41 AM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ROTH MKM initiated coverage on Genelux with a new price target

      ROTH MKM initiated coverage of Genelux with a rating of Buy and set a new price target of $10.00

      8/28/24 7:46:18 AM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Genelux with a new price target

      H.C. Wainwright initiated coverage of Genelux with a rating of Buy and set a new price target of $35.00

      11/27/23 7:16:52 AM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNLX
    Insider purchases explained

    Analytical look into recent insider purchases

    See more
    • What Does the Recent Purchase at Air Transport Services Group Inc on Jun 7 Indicate?

      Recently, on June 7, 2024, Michael L Berger, a significant figure at Air Transport Services Group Inc, made a notable insider purchase. Berger bought $49,830 worth of shares, acquiring 3,996 units at a price of $12.47 per share. This transaction increased his direct ownership by 4% to 103,705 units as reported in the SEC Form 4 here. Examining other insider actions within the company can sometimes reveal intriguing patterns that might offer insights for investors. Looking back at previous transactions, we see a series of insider activities at Air Transport Services Group Inc: In March 2024, Dominick Jeffrey A. filed an SEC Form 4, indicating a notable transaction date in which actions were

      6/10/24 12:35:45 AM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Tyree James L bought 6,250 shares, increasing direct ownership by 181% to 9,710 units (SEC Form 4)

      4 - GENELUX Corp (0001231457) (Issuer)

      6/7/24 9:45:20 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Thomas John bought 2,500 shares, increasing direct ownership by 0.54% to 465,960 units (SEC Form 4)

      4 - GENELUX Corp (0001231457) (Issuer)

      6/7/24 9:45:16 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Smither John W bought 6,250 shares, increasing direct ownership by 90% to 13,170 units (SEC Form 4)

      4 - GENELUX Corp (0001231457) (Issuer)

      6/7/24 9:45:18 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNLX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $GNLX
    Leadership Updates

    Live Leadership Updates

    See more
    • Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates

      WESTLAKE VILLAGE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2025 and provided general business updates.   "The first quarter of 2025 has been highly productive and sets a strong foundation for the year ahead. We are well positioned to advance Olvi-Vec across multiple high-need cancer indications, with encouraging regulatory feedback from the FDA on our OnPrime Phase 3 registrational trial in resistant/refractory ovarian cancer, promising early lung cancer clinical data from our ongoing Phase 1b/2 study, and increasing patient enrollment in our U.S. Ph

      5/6/25 4:10:00 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference

      WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board, and Matt Pulisic, CFO, will discuss clinical-stage programs and upcoming milestones in a fireside chat at the Citizens Life Sciences Conference taking place May 7-8, 2025, in New York. The conversation with Biotech Equity Research Managing Director, Silvan Tuerkcan, PhD, is scheduled to begin at 1:30 p.m. ET on Thursday, May 8, 2025. A webcast link for the event will be available at https://wsw.com/webcast/jmp65/gnlx/1693890. An archived replay will be available for a

      5/1/25 4:05:00 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      – Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer – – Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer – – Matt Pulisic joined the company as its new Chief Financial Officer – – Closing of $10.5 Million Underwritten Offering of Common Stock – – $30.9 million in cash, cash equivalents and short-term investments – WESTLAKE VILLAGE, Calif., March 28, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, reported fourth quarter and full year 2024 financial results and business updates. "Our pr

      3/28/25 4:10:00 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genelux Corporation Announces New Chief Financial Officer

      WESTLAKE VILLAGE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has joined the company as its new Chief Financial Officer, effective January 30, 2025. "I am very pleased to welcome Matt as our new Chief Financial Officer. Matt's financial acumen, strategic mindset and proven leadership abilities are an ideal fit for Genelux," said Thomas Zindrick, President, CEO and Chairman of the Board. "His unique combination of financial expertise and scientific background will be valuable as the company continues building towards the potential launch of Olvi-Vec." Mr. Pulisic is an ac

      2/3/25 6:45:00 AM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GNLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Head of Regulatory Smalling Ralph was granted 4,172 shares, increasing direct ownership by 13% to 36,019 units (SEC Form 4)

      4 - GENELUX Corp (0001231457) (Issuer)

      4/17/25 4:58:47 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP, Pharmaceutical Development Cappello Joseph was granted 13,350 shares, increasing direct ownership by 31% to 57,003 units (SEC Form 4)

      4 - GENELUX Corp (0001231457) (Issuer)

      4/17/25 4:57:32 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP, Clinical Trial Operations Yu Yong was granted 13,350 shares, increasing direct ownership by 33% to 53,219 units (SEC Form 4)

      4 - GENELUX Corp (0001231457) (Issuer)

      4/17/25 4:56:26 PM ET
      $GNLX
      Biotechnology: Pharmaceutical Preparations
      Health Care